Authors : Rajan Kumar; Anjali Bhagria; Sanjiv Duggal

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/bdfhzvr7

Scribd : https://tinyurl.com/6ryp4rjj

DOI : https://doi.org/10.38124/ijisrt/26May844

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : By overcoming the particular anatomical and physiological barriers of the eye, the ocular drug delivery system is a specialist sector that aims to improve the treatment of eye illnesses. Due to quick tear drainage and inadequate medication penetration, conventional techniques like eye drops have poor bioavailability, which lowers their therapeutic efficacy. The structure of the eye, frequent ocular conditions such cataract, glaucoma, dry eye disease, conjunctivitis, and eye stroke, as well as their pathogenesis and therapeutic methods, are the main topics of this project. The study underlines the necessity for sophisticated drug delivery methods and draws attention to the difficulties in delivering medications to both the anterior and posterior parts of the eye. Numerous contemporary methods, including sustained-release systems, insitu gels, and nano formulations, have been proposed to increase drug retention, boost bioavailability, and lower dosing frequency. Furthermore, developments in therapeutic and surgical approaches are investigated, such as phacoemulsification, intraocular lenses, and laser-assisted procedures. In order to enhance patient compliance and therapeutic results in the treatment of ocular disorders, this project offers a thorough overview of ocular drug delivery methods, their drawbacks, and current advancements.

Keywords : Eye Disease, Eye Drops, Cataract, Glaucoma, Dry Eye Disease.

References :

1. Bourne RR, Flaxman SR, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. The Lancet Global Health. 2017 Sep 1;5(9):e888-97.
2. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World journal of pharmacology. 2013 Jun 9;2(2):47.
3. Suri R, Beg S, Kohli K. Target strategies for drug delivery bypassing ocular barriers. Journal of drug delivery science and technology. 2020 Feb 1;55:101389.
4. Mitra AK. Ophthalmic drug delivery systems.
5. Reddy IK. Ocular theraputics and drug delivery. CRC Press; 1995 Dec 12.
6. Palani S, Joseph NM, Goda CC, Zachariah A, Ayenew Z. Ocular drug delivery: a review. Int J Pharm Sci Res. 2010;1(3):1-1.
7. Qi H, Wenwen C, Chunyan H, Li L, Chuming C, Weimin L, and Chunjie W: Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm. 2007; 337:178– 187
8. Krishnaswami V, Kandasamy R, Alagarsamy S, Palanisamy R, Natesan S. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases. International journal of biological macromolecules. 2018 Apr 15;110:7-16.
9. Chitra PS, Chaki D, Boiroju NK, Mokalla TR, Gadde AK, Agraharam SG, et al. Status of oxidative stress markers, advanced glycation index, and polyol pathway in age-related cataract subjects with and without diabetes. Exp Eye Res. 2020; 200:108230. https://doi.org/10.1016/j.exer.2020.108230
10. Leske MC. Open-angle glaucoma—an epidemiologic overview. Ophthalmic epidemiology. 2007 Jan 1;14(4):166-72.
11. Isenberg SJ. Physical and refractive characteristics of the eye at birth and during infancy. The eye in infancy. 2nd edition. St. Louis: Mosby. 1994:36-51.
12. Gordon RA, Donzis PB. Refractive development of the human eye. Arch Ophthalmology 1985; 103:785-9.
13. Hitzenberger CK. Optical measurement of the axial eye length by laser Doppler interferometry. Investigative ophthalmology & visual science. 1991 Mar 1;32(3):616-24.
14. Schmid GF, Papastergiou GI, Nickla DL, Riva CE, Lin T, Stone RA, Laties AM. Validation of laser Doppler interferometric measurements in vivo of axial eye length and thickness of fundus layers in chicks. Current eye research. 1996 Jan 1;15(6):691-6.
15. Goto E, Monden Y, Takano Y, Mori A, Shimmura S, Shimazaki J, Tsubota K. Treatment of non-inflamed obstructive meibomian gland dysfunction by an infrared warm compression device. British Journal of Ophthalmology. 2002 Dec 1;86(12):1403-7.
16. Greiner JV. Long‐term (12‐month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clinical & experimental ophthalmology. 2013 Aug;41(6):524-30.
17. Meier P, Wiedemann P. Surgery for pediatric vitreoretinal disorders. InRetina 2013 Jan 1 (pp. 1933-1953). WB Saunders.
18. Wei N, Bi H, Zhang B, Li X, Sun F, Qian X. Biphasic growth of orbital volume in Chinese children. British Journal of Ophthalmology. 2017 Sep 1;101(9):1162-7.
19. Waitzman AA, Posnick JC, Armstrong DC, Pron GE. Craniofacial skeletal measurements based on computed tomography: Part II. Normal values and growth trends. The Cleft Palate-Craniofacial Journal. 1992 Mar;29(2):118-28.
20. Bron AJ, Tripathi RC, Tripathi BJ. The bony orbit and paranasal sinuses. Wolff’s Anatomy of the Eye and Orbit. 1997;8:1-29.
21. Singh M, Bharadwaj S, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. Journal of Controlled Release. 2020 Dec 10;328:895-916.
22. Krishnaswami V, Kandasamy R, Alagarsamy S, Palanisamy R, Natesan S. Biological macromolecules for ophthalmic drug delivery to treat ocular diseases. Int J Biol Macromol. 2018; 110:7–16.
23. Leske MC. Open-angle glaucoma—an epidemiologic overview. Ophthalmic epidemiology. 2007 Jan 1;14(4):166-72.
24. Elsayed I, Sayed S. Tailored nanostructured platforms for boosting transcorneal permeation: Box–Behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization. International Journal of Nanomedicine. 2017 Oct 30:7947-62.
25. Randazzo J, Zhang P, Makita J, Blessing K, Kador PF. Orally active multi-functional antioxidants delay cataract formation in streptozotocin (type 1) diabetic and gamma-irradiated rats. PloS one. 2011 Apr 26;6(4):e18980.
26. Lu A, Duan P, Xie J, Gao H, Chen M, Gong Y, et al. Recent progress and research trend of anti-cataract pharmacology therapy: a bibliometric analysis and literature review. Eur J Pharmacol. 2022; 934:175299.
27. Atkinson J, Anker S, Bobier W, Braddick O, Durden K, Nardini M, Watson P. Normal emmetropization in infants with spectacle correction for hyperopia. Investigative ophthalmology & visual science. 2000 Nov 1;41(12):3726-31.
28. Magli A, Forte R, Carelli R, Rombetto L, Magli G. Long-term outcomes of primary intraocular lens implantation for unilateral congenital cataract. InSeminars in ophthalmology 2016 Nov 1 (Vol. 31, No. 6, pp. 548-553). Taylor & Francis..
29. Harbo HF, Gold R, Tintoré M. Sex and gender issues in multiple sclerosis. Therapeutic advances in neurological disorders. 2013 Jul;6(4):237-48.
30. Takata T, Matsubara T, Nakamura-Hirota T, Fujii N. Negative charge at aspartate 151 is important for human lens αA-crystallin stability and chaperone function. Experimental eye research. 2019 May 1;182:10-8.
31. Khamkar SG, Barkade GD. Review on cataract. Indian Journal of Cataract and Refractive Surgery. 2024 Apr 1;1(2):112-24.
32. Khamkar SG, Barkade GD. Review on cataract. Indian Journal of Cataract and Refractive Surgery. 2024 Apr 1;1(2):112-24.
33. asgeyehospital.com/blog/6-benefits-of-modern-cataract-treatment-techniques
34. Katargina LA, Kruglova TB, Trifonova OB, Egiyan NS, Kogoleva LV, Arestova NN. Refraction in pseudophakic eyes after surgical treatment of congenital cataracts. Vestnik Oftalmologii. 2019 Jan 1;135(1):36-41.
35. Aly MG, Shams A, Fouad YA, Hamza I. Effect of lens thickness and nuclear density on the amount of laser fragmentation energy delivered during femtosecond laser–assisted cataract surgery. Journal of Cataract & Refractive Surgery. 2019 Apr 1;45(4):485-9.
36. Ren Y, Fang X, Fang A, Wang L, Jhanji V, Gong X. Phacoemulsification with 3.0 and 2.0 mm opposite clear corneal incisions for correction of corneal astigmatism. Cornea. 2019 Sep 1;38(9):1105-10.
37. Barabino S, Aragona P, di Zazzo A, Rolando M, with the Contribution of Selected Ocular Surface Experts from the Società Italiana di Dacriologia e Superficie Oculare. Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques. European Journal of Ophthalmology. 2021 Jan;31(1):42-8.
38. Navarro-Lopez S, Moya-Ramon M, Gallar J, Carracedo G, Aracil-Marco A. Effects of physical activity/exercise on tear film characteristics and dry eye associated symptoms: A literature review. Contact Lens and Anterior Eye. 2023 Aug 1;46(4):101854.
39. De Paiva CS, Corrales RM, Villarreal AL, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Investigative ophthalmology & visual science. 2006 Jul 1;47(7):2847-56.
40. Dursun D, Wang M, Monroy D, Li DQ, Lokeshwar BL, Stern ME, Pflugfelder SC. A mouse model of keratoconjunctivitis sicca. Investigative ophthalmology & visual science. 2002 Mar 1;43(3):632-8.
41. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye & contact lens. 2005 Sep 1;31(5):186-93.
42. Corrales RM, Stern ME, De Paiva CS, Welch J, Li DQ, Pflugfelder SC. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Investigative ophthalmology & visual science. 2006 Aug 1;47(8):3293-302.
43. De Paiva CS, Corrales RM, Villarreal AL, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Investigative ophthalmology & visual science. 2006 Jul 1;47(7):2847-56.
44. De Paiva CS, Corrales RM, Villarreal AL, Farley WJ, Li DQ, Stern ME, Pflugfelder SC. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Experimental eye research. 2006 Sep 1;83(3):526-35.
45. De Paiva CS, Villarreal AL, Corrales RM, Rahman HT, Chang VY, Farley WJ, Stern ME, Niederkorn JY, Li DQ, Pflugfelder SC. Dry eye–induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ. Investigative ophthalmology & visual science. 2007 Jun 1;48(6):2553-60.
46. Prinz J, Maffulli N, Fuest M, Walter P, Bell A, Migliorini F. Efficacy of topical administration of corticosteroids for the management of dry eye disease: systematic review and meta-analysis. Life. 2022 Nov 19;12(11):1932.
47. Yao YF, Wang MY, Dou XY. Gastrointestinal microbiome and primary Sjögren's syndrome: a review of the literature and conclusions. International Journal of Ophthalmology. 2022 Nov 18;15(11):1864.
48. Pflugfelder SC, Geerling G, Kinoshita S, Lemp MA, McCulley JP, Nelson D, Novack GN, Shimazaki J, Wilson C. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocular Surface. 2007 Apr;5(2):163-78.
49. Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean Journal of Ophthalmology. 2005 Dec 1;19(4):258-63.
50. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Investigative ophthalmology & visual science. 2011 Apr 1;52(5):2525-31.
51. Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 2010 Jul 1;29(7):781-8.
52. Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G. Systemic linoleic and γ-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 2003 Mar 1;22(2):97-101.
53. Geerling G, Tauber J, Baudouin C, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011; 52:2050–2064. doi: 10.1167/iovs.10-6997g. [DOI] [PMC free article] [PubMed] [Google Scholar]
54. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR. The clinical efficacy of silicone punctal plug therapy. Cornea. 2002; 21:135–139. doi: 10.1097/00003226-200203000-00001. [DOI] [PubMed] [Google Scholar]
55. Stern ME, Schaumburg CS, Pflugfelder SC. Dry eye as a mucosal autoimmune disease. International reviews of immunology. 2013 Jan 13;32(1):19-41.
56. Pflugfelder SC, Geerling G, Kinoshita S, Lemp MA, McCulley JP, Nelson D, Novack GN, Shimazaki J, Wilson C. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocular Surface. 2007 Apr;5(2):163-78.
57. Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optometry and vision science. 2012 Nov 1;89(11):1654-61.
58. Messmer EM. Preservatives in ophthalmology. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012 Nov 1;109(11):1064-70.
59. Giri BR, Poudel S, Kim DW. Cellulose and its derivatives for application in 3D printing of pharmaceuticals. Journal of Pharmaceutical Investigation. 2021 Jan;51(1):1-22.
60. Hasan N, Cao J, Lee J, Kim H, Yoo JW. Development of clindamycin-loaded alginate/pectin/hyaluronic acid composite hydrogel film for the treatment of MRSA-infected wounds. Journal of Pharmaceutical Investigation. 2021 Sep;51(5):597-610.
61. Kim MH, Nguyen DT, Kim DD. Recent studies on modulating hyaluronic acid-based hydrogels for controlled drug delivery. Journal of Pharmaceutical Investigation. 2022 Jul;52(4):397-413.
62. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999 Apr 1;106(4):811-6.
63. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, Bartels SP, Micuda T, Proskin HM, Vogel R. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. American journal of ophthalmology. 2004 Sep 1;138(3):444-57.
64. Dursun D, Ertan A, Bilezikçi B, Akova YA, Pelit A. Ocular surface changes in keratoconjunctivitis sicca with silicone punctum plug occlusion. Current eye research. 2003 Jan 1;26(5):263-9.
65. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000 May 1;47(2-3):119-25.
66. Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012 Aug 1;31(8):945-9.
67. Sanz-Marco, E.; Udaondo, P.; García-Delpech, S.; Vazquez, A.; Diaz-Llopis, M. Treatment of Refractory Dry Eye Associated with Graft versus Host Disease with 0.03% Tacrolimus Eyedrops. J. Ocul. Pharmacol. Ther. 2013, 29, 7
68. Auw-Hädrich C, Reinhard T. Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2009 Jul 1;106(7):635-8.
69. Guzman-Aranguez A, Fonseca B, Carracedo G, Martin-Gil A, Martinez-Aguila A, Pintor J. Dry eye treatment based on contact lens drug delivery: a review. Eye & contact lens. 2016 Sep 1;42(5):280-8.
70. Messmer, E.M. Pathophysiology, Diagnosis and Treatment of Dry Eye. Dtsch. Arzt blatt Int. 2015, 112, 71–82
71. Yoo, S.E.; Lee, D.C.; Chang, M.H. The Effect of Low-Dose Doxycycline Therapy in Chronic Meibomian Gland Dysfunction. Korean J. Ophthalmol. KJO 2005, 19, 258–263.
72. Solomon A, Rosenblatt M, Li DQ, Liu Z, Monroy D, Ji Z, Lokeshwar BL, Pflugfelder SC. Doxycycline inhibition of interleukin-1 in the corneal epithelium. Investigative ophthalmology & visual science. 2000 Aug 1;41(9):2544-57.
73. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R. Effect of topical azithromycin on corneal innate immune responses. Investigative ophthalmology & visual science. 2011 Apr 1;52(5):2525-31.
74. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, De Simone G, Ford ES, Fox CS. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation. 2011 Feb 1;123(4):e18-209.
75. Shakir R. The struggle for stroke reclassification. Nature Reviews Neurology. 2018 Aug;14(8):447-8.
76. Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, Moomaw CJ, Schneider A, Kissela B, Kleindorfer D, Broderick JP. Racial variations in location and risk of intracerebral hemorrhage. Stroke. 2005 May 1;36(5):934-7.
77. Cherney LR, Halper AS, Papachronis D. Two approaches to treating unilateral neglect after right hemisphere stroke: a preliminary investigation. Topics in stroke rehabilitation. 2003 Jan 1;9(4):22-33.
78. Shekhawat NS, Shtein RM, Blachley TS, Stein JD. Antibiotic prescription fills for acute conjunctivitis among enrollees in a large United States managed care network. Ophthalmology 2017; 124:1099–1107
79. Owen CG, Shah A, Henshaw K, Smeeth L, Sheikh A. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. The British Journal of General Practice. 2004 Jun 1;54(503):451.
80. Broide DH. Immunomodulation of allergic disease. Annual review of medicine. 2009 Feb 18;60(1):279-91.
81. Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, Keil U. Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Münster, Germany. Allergy. 2003 Jul;58(7):572-9.
82. Rathi VM, Murthy SI. Allergic conjunctivitis. Community eye health. 2017;30(99):S7.
83. Patel KD, Silva LB, Park Y, Shakouri T, Keskin-Erdogan Z, Sawadkar P, Cho KJ, Knowles JC, Chau DY, Kim HW. Recent advances in drug delivery systems for glaucoma treatment. Materials Today Nano. 2022 Jun 1;18:100178.
84. Swaminathan SS, Quist MS, Dawson LE, Rothman AL, Herndon LW. Effect of nylon wick technique on early intraocular pressure control in nonvalved aqueous shunt surgery. Journal of glaucoma. 2021 Jan 1;30(1):32-6.
85. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma: II. The site of injury and susceptibility to damage. Archives of ophthalmology. 1981 Apr 1;99(4):635-49.
86. McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R, Los Angeles Latino Eye Study Group. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008 Jun 1;115(6):941-8.